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Abstract
Background: Studies of treatment with octreotide of patients with hepatocellular carcinoma
(HCC) gave conflicting results. We analyzed retrospectively the survival of our patients treated
with octreotide monotherapy and compared it to stage-matched patients who received either
TACE, multimodal therapy or palliative care.
Methods: 95 patients seen at the department of Gastroenterology and Hepatology, Medical
University of Vienna with HCC in BCLC stage A or B, who received either TACE, multimodal
therapy, long-acting octreotide or palliative care were reviewed for this retrospective study.
Results: Survival rates of patients with BCLC stage B and any "active" treatment (long-acting
octreotide, TACE or multimodal therapy) were significantly higher (22.4, 22.0, 35.5 months)
compared to patients who received palliative care only (2.9 months). Survival rates of patients with
BCLC stage A and "active" treatment (31.4, 37.3, 40.2 months) compared to patients who received
only palliative care (15.1 months) did not show statistically significant differences. Octreotide
monotherapy showed a similar outcome compared to patients who received TACE or multimodal
therapy.
Conclusion:  Survival under octreotide treatment was not different compared to TACE or
multimodal therapy and might be a therapeutic option for patients with HCC.
Introduction
Hepatocellular carcinoma is a sequel of chronic liver dis-
ease and shows high and increasing prevalence world-
wide. In most cases it is associated with the presence of
liver cirrhosis and has a poor prognosis with an overall
median survival of 8 months in Austria [1]. To assess the
survival of patients with hepatocellular carcinoma differ-
ent prognostic models have been developed [2-5].
Although no staging system has emerged as standard, one
of the most widely used survival model is the BCLC (Bar-
celona Clinic Liver Cancer) staging system [2] which
appears to be the most comprehensive, as it links staging
to treatment [5]. Treatment options which aim to obtain
clinical cure include liver resection, liver transplantation
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and various forms of local ablation, such as percutaneous
ethanol injection (PEI) or radiofrequency ablation. These
treatment modalities are only available for patients with
early stage hepatocellular carcinomas (patients with BCLC
stage A and B). Patients who present with an advanced
stage of HCC (Patients with BCLC stage C) will currently
be treated, among other modalities, with transarterial
chemoembolisation (TACE) or the multi-thyrosin-kinase
inhibitor sorafenib [6]. This treatment aims to prolong
survival while maintaining the best possible quality of
life. Other patients with advanced hepatocellular carci-
noma may participate in clinical studies for new treatment
modalities or substances, respectively.
One substance which has been discussed controversially
in the last years is octreotide. Somatostatin and its syn-
thetic analogues, octreotide and lanreotide are potentially
active against HCC due to their antiproliferative and
apoptosis-inducing activity; in addition HCC has been
shown to overexpress somatostatin receptors on the cell
surface [7-10]. Several years ago Kouroumalis et al [11]
published a randomized controlled trial which showed a
significantly improved survival in patients with inopera-
ble hepatocellular carcinoma treated with octreotide as
compared to placebo (13.0 versus 4.0 months). In addi-
tion, a second randomized placebo-controlled trial [12]
showed an improved survival (49.0 versus 28.0 weeks)
and quality of life in patients with advanced hepatocellu-
lar carcinoma treated with long-acting octreotide. In con-
trast, Yuen et al [13] did not find a survival benefit of
octreotide-monotherapy in patients with advanced hepa-
tocellular carcinoma. Similarly, a large German study [14]
reported an equally poor median survival in the treatment
group (4.7 months) and the control group (5.3 months),
respectively. It is interesting to note that in the two nega-
tive studies [13,14] the median survival of octreotide
treated patients and the control group was extremely poor
making it difficult to show any possible influence of octre-
otide treatment on survival. In contrast, in the two posi-
tive studies [11,12] survival even in the placebo arms was
considerably longer suggesting differences in patient
selection.
Due to these divergent study results concerning the influ-
ence of octreotide on survival we decided to analyze retro-
spectively the survival of our patients with hepatocellular
carcinoma and octreotide monotherapy and compared it
to stage-matched patients who received either TACE, mul-
timodal therapy or palliative care.
Patients and methods
Patient characteristics
The charts of all patients with hepatocellular carcinoma
(HCC) seen at the department of Gastroenterology and
Hepatology, Medical University of Vienna from 1992 to
2004 were reviewed for this retrospective study. At the
time of diagnosis 95 of these patients were in BCLC [2]
stage A or B and received either TACE, multimodal ther-
apy, long-acting octreotide [Sandostatin LAR] or palliative
care. Stage A patients receiving that treatment modalities
declined other treatment options such as liver transplan-
tation or resection or were not candidates for this proce-
dures due to older age or concomitant diseases. We
focused on reporting the results of stage A and B patients
because most of the patients in advanced BCLC stages
(stage C and D) received only palliative care and no active
treatment at that time. Furthermore, patients with
advanced BCLC stages typically suffer from complications
of terminal liver cirrhosis which has a considerable influ-
ence on survival. To minimize the influence of the under-
lying liver disease and to focus on the impact of tumour
treatment on survival, patients with advanced BCLC
stages were excluded. MELD scores within the BCLC stages
A and B, respectively and various treatment modalities
were not statistically significant when tested allowing for
multiple comparisons (p = 0.07).
The demographic data and clinical characteristics are
given in Table 1. Liver cirrhosis was diagnosed either by
histology or by the typical combination of laboratory
tests, clinical and gastroscopic findings and typical signs
of liver cirrhosis in CT or ultrasound. Diagnosis of hepa-
tocellular carcinoma was done according to the criteria of
EASL [15] and AASLD [16]. Histologic confirmation was
performed in 31 of 40 (77.5%) patients in BCLC stage A
and 50 of 55 (90.9%) patients with BCLC stage B. Overall,
hepatocellular carcinoma was histologically confirmed in
85.3% of our patients.
Treatment modalities
Long-acting Octreotide [Sandostatin LAR]
30 mg long-acting octreotide (Sandostatin-LAR™,
Novartis, Basel, Switzerland) was given i.m. once a month
until death.
This therapy was given within the context of an unpub-
lished study to compare the clinical outcome of addi-
tional percutaneous ethanol instillation (PEI) against no
further treatment in patients with HCC, all receiving hor-
monal treatment with long-acting octreotide. All patients
(n = 25) who received only treatment with long-acting
octreotide were included in this retrospective comperative
study. Patients who received a combination therapy with
long-acting octreotide and percutaneous ethanol instilla-
tion (PEI) were excluded.
Transarterial (Chemo-) embolization (TAE/TACE)
Transarterial (Chemo-) embolization (TAE/TACE) as ther-
apy (n = 17) was chosen in patients with BCLC stage B
(advanced tumor without evidence of distant metastasesJournal of Experimental & Clinical Cancer Research 2009, 28:142 http://www.jeccr.com/content/28/1/142
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or vessel invasion). Furthermore, patients with BCLC
stage A were treated with transarterial embolization (TAE)
or transarterial chemoembolization (TACE) in case of
contraindications for orthotopic liver transplantation
(OLT), liver resection or percutaneous local therapy.
TAE was performed according to a standardized tech-
nique. The femoral artery was cannulated under local
anesthesia, and diagnostic angiography of the celiac trunk
and superior mesenteric artery was performed. After iden-
tification of the vascular anatomy, a superselective cathe-
ter was pushed forward into the hepatic arteries by use of
a guide wire. Afterwards, different mixtures of substances
for embolization were used during the time period we
analyzed in this retrospective study. First, there was a mix-
ture of N-butyl-2-cyanoacrylate (Histoacryl blue; B.
Braun, Melsungen, Germany) and ethiodized oil (Lipi-
odol Ultrafluide; Guerbet, Villepinte, France) as an
embolic agent. Secondly in case of TACE a mixture of dox-
orubicin and ethiodized oil (Lipiodol Ultrafluide; Guer-
bet, Villepinte, France) as an embolic agent was used.
TAE/TACE was performed superselectively by occluding
only the tumor-feeding segmental arteries or selectively by
occluding the right or left hepatic artery. In general, a
superselective embolization was aimed. However, in
patients with a large tumour mass or more than one nod-
ule in the same lobe, selective embolization of the entire
lobe was performed. In patients with tumor disease in
both the right and the left liver lobe, only one lobe was
embolized during one treatment session to avoid a pro-
longed postembolization syndrome or postinterventional
liver failure. A completion arteriogram was obtained to
confirm occlusion of the embolized vessels. After TAE/
TACE, the patients were carefully observed and side-
effects of embolization were treated symptomatically. Fol-
low-up was done with contrast-enhanced CT of the liver
to assess the effect of embolization on the tumor.
Depending on success of the already performed interven-
tions embolization sessions were repeated in intervals
from 1 to 3 months.
Multimodal therapy
Multimodal therapy (n = 17) included a combination of
local ablative therapies such as percutaneous ethanol
instillation (PEI), radiofrequency ablation therapy or cry-
otherapy on the one hand and transarterial embolization
therapy as described above on the other hand. Usually
Table 1: Characteristics of patients with HCC according to treatment modalities
Sandostatin LAR TACE multimodal therapy palliative care
BCLC A BCLC B BCLC A BCLC B BCLC A BCLC B BCLC A BCLC B
number 11 14 5 9 7 10 17 22
Sex
m a l e 61 04 8 7 91 4 1 6
f e m a l e54110136
liver 
cirrhosis
n o 00021022
yes 11 14 5 7 6 10 15 20
Child-Pugh-
classification
C h i l d  A 9 1 2 135877
C h i l d  B 2244128 1 3
C h i l d  C 00000000
MELD 
(median/
range)
7.33 
(0.27-15.98)
7.61 
(0.16-15.0)
14.60 
(11.13-
17.35)
11.46 
(6.68-16.90)
11.56 
(6.78-49.26)
8.98 
(7.15-16.01)
12.31 
(4.66-58.20)
13.20 
(1.53-49.82)
Etiology
Alcoholism 5 8 2 4 5 3 8 8
chronic 
hepatitis B
10001020
chronic 
hepatitis C
44321757
o t h e r s12030026
Age 
(median/
range)
66.5 
(53.7-80.5)
68.7 
(49.4-73.4)
64.9 
(63.6-69.2)
68.4 
(48.4-78.4)
50.5 
(47.4-64.6)
69.9 
(61.2-76.9)
68.5 
(43.1-81.2)
62.5 
(44.8-73.4)Journal of Experimental & Clinical Cancer Research 2009, 28:142 http://www.jeccr.com/content/28/1/142
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percutaneous ablative therapies were given first, after
signs of tumour progression were seen treatment was con-
tinued with TAE/TACE.
Palliative care
39 patients received only symptomatic therapy but no
active treatment for hepatocellular carcinoma. Patients in
this group rejected the offered local ablative therapies,
embolization therapy or systemic treatment but opted for
palliative care only.
Statistical analysis
Chi2 test was used to compare proportions and Mann
Whitney U tests to compare median values between
groups. Survival times were estimated using the Kaplan-
Meier method and the differences were tested with the
log-rank test. Analysis was performed with Statistica
(StatSoft, Inc. (2004). STATISTICA (data analysis software
system), version 6. http://www.statsoft.com).
Results
Patients with BCLC stage A
40 patients were classified to BCLC stage A. Treatment
modalities in this group were: long-acting octreotide [San-
dostatin LAR] (n = 11 [27.5%]), TACE (n = 5 [12.5%]),
multimodal therapy as defined above (n = 7 [17.5%]) and
palliative care only (17 [42.5%]).
Median Survival (Figure 1)
Overall median survival was 18.4 months. Median sur-
vival rates in long-acting octreotide [Sandostatin LAR],
TACE, multimodal therapy and palliative care were 31.4,
37.3, 40.2 and 15.1 months respectively (Table 2).
Although survival rates of patients with "active" treatment
(long-acting octreotide [Sandostatin LAR], TACE or multi-
modal therapy) were more than twice as long as of
patients who received only palliative care this difference
was not significant. Survival rates of patients with various
active treatment modalities did not differ significantly.
The 1 year survival rate in the long-acting octreotide [San-
dostatin LAR] group was 64% and in patients who
received multimodal therapy, TACE, and palliative care
86%, 80% and 53%, respectively. The 2 year survival rate
in the long-acting octreotide [Sandostatin LAR] group was
55% and in patients who received multimodal therapy,
TACE, and palliative care 82%, 60% and 29%, respec-
tively.
Patients with hepatocellular carcinoma and BCLC stage A Figure 1
Patients with hepatocellular carcinoma and BCLC stage A. Median survival rates in long-acting octreotide [Sandosta-
tin LAR], TACE, multimodal therapy and palliative care were 31.4, 37.3, 40.2 and 15.1 months respectively. Survival rates of 
patients with active treatment did not differ significantly.Journal of Experimental & Clinical Cancer Research 2009, 28:142 http://www.jeccr.com/content/28/1/142
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Patients with BCLC Stage B
55 patients were classified as BCLC stage B. These patients
received long-acting octreotide [Sandostatin LAR] (n = 14
[25.4%]), TACE (n = 9 [16.4%]), multimodal therapy as
defined above (n = 10 [18.2%]) and palliative care (n = 22
[40.0%]), respectively.
Median Survival (Figure 2)
Overall median survival was 15.1 months. Median sur-
vival rates of the group receiving long-acting octreotide
[Sandostatin LAR], TACE, multimodal therapy and pallia-
tive care were 22.4, 22.0, 35.5 and 2.9 months, respec-
tively (Table 2). Survival rates of patients with "active"
treatment (long-acting octreotide [Sandostatin LAR],
TACE or multimodal therapy) were significantly higher
than of patients who received palliative care only (log
rank test: P = 0.00043, P = 0.00151, P = 0.00005). Median
survival among patients with various "active" treatment
forms did not show significant differences (log rank test:
P > 0.05).
The 1 year survival rate in the long-acting octreotide [San-
dostatin LAR] group was 64% and in patients who
received multimodal therapy, TACE, and palliative care
90%, 78% and 23%, respectively. The 2 year survival rate
in the long-acting octreotide [Sandostatin LAR] group was
36% and in patients who received multimodal therapy,
TACE, and palliative care 80%, 34% and 5%, respectively.
Discussion
In the present paper we studied retrospectively the influ-
ence of octreotide monotherapy (long-acting octreotide
[Sandostatin LAR]) on survival of patients with hepatocel-
lular carcinoma and compared it to BCLC stage-matched
patients who received either TACE, multimodal therapy or
palliative care only. Our data showed that survival rates of
patients with BCLC stage B and any "active" treatment
(long-acting octreotide [Sandostatin LAR], TACE or multi-
modal therapy) were significantly higher as compared to
patients who received palliative care only. Although sur-
vival time of patients with BCLC stage A and "active" treat-
ment (long-acting octreotide [Sandostatin LAR], TACE or
multimodal therapy) were more than twice as long as of
patients who received palliative care only this difference
was not statistically significant. Median survival among
patients with various forms of "active" treatment did not
show significant differences (BCLC stage A and B; log rank
test: P > 0.05). In particular, octreotide monotherapy
showed a similar outcome compared to patients who
received TACE or multimodal therapy.
Kouroumalis et al [11] for the first time published a
patient population with advanced liver disease (only
3.6% of the patients had Child-Pugh stage A) and HCC
treated with octreotide. The treatment group had an excel-
lent median survival of 13.0 months as compared to 4.0
months in the control group, suggesting a beneficial effect
of octreotide treatment in this patient population. Simi-
larly, Dimitroulopoulos et al [12] recently reported the
results of a randomised placebo-controlled trial which
showed a significantly higher survival in somatostatin
receptor positive patients receiving long-acting octreotide
[Sandostatin LAR] as compared to placebo.
In contrast, the patient population in the randomized
controlled trial of Yuen et al [13] had a very poor survival
of only 1.93 months in the treatment group and 1.97
months in the control group, respectively. This very poor
survival in treatment and control group is remarkable
because the majority (51.4%) of the patients included in
the treatment group had stage A according to the Child-
Pugh classification. Besides, only 8.6% of these patients
were in Child-Pugh stage C and 17.1% in Okuda stage III.
Therefore the poor outcome of these patients is not
reflected in both the Child-Pugh classification (8.6%
Child-Pugh Stage C) and the Okuda staging system
(17.1% in Okuda stage III). However, nearly half of the
patients had a portal vein thrombosis corresponding to
advanced disease BCLC stage C and the poor median sur-
vival of less than 2 months in treatment and control group
indicates terminal liver disease. Finally, due to the bad
survival 13 out of 35 patients from the treatment group
Table 2: Patient survival according to BCLC stage and treatment
BCLC A BCLC B
number median survival 
(months)
log rank test number median survival 
(months)
log rank test
number treatment 
modalities
40 55
Sandostatin LAR 11 31.4 P = 0.35038 14 22.4 P = 0.00003
TACE 5 37.3 9 22.0
multimodal therapy 7 40.2 10 35.5
palliative care 17 15.1 22 2.9Journal of Experimental & Clinical Cancer Research 2009, 28:142 http://www.jeccr.com/content/28/1/142
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died before receiving a single dose of long-acting octre-
otide [Sandostatin LAR]. It is obvious that a positive effect
of Sandostatin LAR could only be expected in patients
receiving some minimal doses of Sandostatin LAR. There-
fore, it seems that the patients in the study of Yuen [13]
did not live long enough to benefit from Sandostatin LAR
therapy. Similarly, the overall poor survival in both treat-
ment and placebo controlled groups of the recently pub-
lished HECTOR study (Becker et al [14]) might be the
reason for the inability of detecting a survival difference
between these two groups. However, also two recent stud-
ies could not demonstrate a statistically significant sur-
vival benefit in patients with advanced hepatocellular
carcinoma treated with long-acting octreotide [Sandosta-
tin LAR] [17,18].
The expression of somatostatin receptors is variable and
only 41% of HCC express this receptor on the cell surface
[7]. Recently, Bläcker et al [19] showed that in HCC
mostly somatostatin receptor subtype III and V are
expressed. On the other hand Reyneart found somatosta-
tin receptor I and II expressed on HCC [20]. Given that
heterogeneity in expression of somatostatin receptor sub-
types both the antiproliferative effect of octreotide and the
response rate might be determined by the expression level
of various somatostatin receptors on HCC which seems to
be independent of histology, underlying liver disease or
tumour stage [17]. This might explain differences of the
therapeutic effects on survival by long-acting octreotide
[Sandostatin LAR] reported in the literature. Indeed Dim-
itroulopoulos et [12] al showed recently that patients with
Somatostatin receptor high expressing tumours survived
longer than patients with low expression.
TACE treatment has been shown to improve survival of
patients with HCC in a metaanalysis of randomized con-
trolled trials [21,22]. It is surprising that in our retrospec-
tive study survival of patients with long-acting octreotide
[Sandostatin LAR] alone was similar to TACE treatment or
multimodal treatment. Although a selection bias cannot
be completely excluded, the patients were comparable as
tumour stage, overall liver function and clinical perform-
ance status, variables comprising the BCLC staging sys-
tem, are concerned. The therapeutic potential of
octreotide is further stressed by the fact that BCLC stage-
matched patients receiving no active treatment had a
shorter survival time than patients with TACE treatment as
expected from the well known fact of a survival benefit of
TACE therapy [19,20]. And yet, TACE treatment was not
better than octreotide treatment. Along the same line, the
Patients with hepatocellular carcinoma and BCLC stage B Figure 2
Patients with hepatocellular carcinoma and BCLC stage B. Median survival rates in long-acting octreotide [Sandostatin 
LAR], TACE, multimodal therapy and palliative care were 22.4, 22.0, 35.5 and 2.9 months respectively. Median survival among 
patients with "active" treatment did not show significant differences (log rank test: P > 0.05).Journal of Experimental & Clinical Cancer Research 2009, 28:142 http://www.jeccr.com/content/28/1/142
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study of Plentz et al [23] showed a similar survival of
patients treated with octreotide compared to patients
treated with TACE.
Treatment with long-acting octreotide [Sandostatin LAR]
was excellently tolerated except for a few episodes of soft
stools presumably due to the effect of reduced exocrine
pancreatic output. This could easily be corrected either
with supplementation of pancreatin containing capsules
or with loperamid tablets. No intramuscular haematoma
formation was observed after i.m. administration of long-
acting octreotide [Sandostatin LAR] despite reduced coag-
ulation capacitiy.
The interpretation of our data might be limited by the ret-
rospective non-randomised nature of our study and the
long time period of recruitment of patients which results
in a considerable heterogeneity of the study groups.
Although, we tried to match the patients in the study
groups according to the BCLC system, the best available
prognostic staging system, residual heterogeneity in the
study population might have influenced the results. In
addition, patients under octreotide treatment tended to
have lower MELD scores than patients undergoing other
treatment modalities although there was no overall differ-
ence in MELD score between the various groups.
In summary, this retrospective analysis of survival of
BCLC stage-matched patients with HCC showed that
octreotide treatment produces a similar survival benefit as
TACE or multimodal therapy as compared to no active
treatment. Given the few side effects of long-acting octre-
otide [Sandostatin LAR] this treatment seems to be a ther-
apeutic option for patients with HCC and needs further
randomised controlled studies in BCLC stage-matched
patients.
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